Acute lymphocytic leukemia
Information
- Disease name
- Acute lymphocytic leukemia
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00586391 | Active, not recruiting | Phase 1 | CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL | February 2009 | July 2029 |
| NCT02315612 | Active, not recruiting | Phase 1 | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies | December 12, 2014 | June 1, 2040 |
| NCT05923112 | Active, not recruiting | BESPONSA Injection 1 mg Special Investigation | July 2, 2018 | August 16, 2024 | |
| NCT03674411 | Active, not recruiting | Phase 2 | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | January 2, 2019 | June 28, 2024 |
| NCT05326516 | Active, not recruiting | Phase 1 | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | March 9, 2022 | June 2024 |
| NCT05292898 | Active, not recruiting | Phase 1 | A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia | March 14, 2022 | July 2026 |
| NCT01430390 | Active, not recruiting | Phase 1 | In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies | September 2011 | September 2026 |
| NCT03755414 | Active, not recruiting | Phase 1 | Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | September 4, 2019 | September 5, 2024 |
| NCT00313079 | Completed | Phase 1 | Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia | May 2006 | July 2009 |
| NCT00349596 | Completed | Phase 1 | A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) | July 2006 | October 2014 |
| NCT00352677 | Completed | Phase 1 | Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia | July 2006 | May 2008 |
| NCT00412360 | Completed | Phase 3 | Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) | December 2006 | October 2014 |
| NCT00467961 | Completed | Phase 2 | Stem Cell Transplantation for Patients With Cancers of the Blood | April 2007 | November 2012 |
| NCT00516152 | Completed | Phase 2 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | November 2002 | November 2007 |
| NCT00571662 | Completed | Phase 2 | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | December 8, 2000 | December 30, 2008 |
| NCT00674479 | Completed | Phase 2 | INCB018424 in Patients With Advanced Hematologic Malignancies | May 12, 2008 | March 23, 2017 |
| NCT00697684 | Completed | Phase 1 | Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant | June 2008 | November 2023 |
| NCT00701844 | Completed | N/A | Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors | July 2007 | September 2011 |
| NCT00773149 | Completed | Phase 1/Phase 2 | Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia | October 2006 | July 2011 |
| NCT00854646 | Completed | Phase 1 | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | October 2008 | December 2015 |
| NCT00001689 | Completed | Phase 1 | A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia | January 1998 | November 2003 |
| NCT00061581 | Completed | Phase 2 | Experimental Bone Marrow Transplant Protocol | May 19, 2003 | June 14, 2017 |
| NCT00089596 | Completed | Phase 1/Phase 2 | Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | March 2004 | October 2006 |
| NCT00098033 | Completed | Phase 2 | Investigation of Clofarabine in Acute Leukemias | September 2002 | September 2005 |
| NCT00145626 | Completed | Phase 2 | HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies | May 2004 | July 2016 |
| NCT00176462 | Completed | Phase 2 | CINJALL: Treatment for Children With Acute Lymphocytic Leukemia | February 2001 | September 2008 |
| NCT00251368 | Completed | Phase 1 | Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia | January 1995 | September 2007 |
| NCT00309842 | Completed | Phase 2 | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | July 28, 2005 | November 22, 2019 |
| NCT00968253 | Completed | Phase 1/Phase 2 | RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia | November 2009 | December 2015 |
| NCT00975975 | Completed | Phase 2 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | September 2009 | November 2013 |
| NCT00990587 | Completed | Phase 1 | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | October 2009 | |
| NCT01075425 | Completed | Phase 1 | Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome | May 2010 | February 2015 |
| NCT01167166 | Completed | Phase 1/Phase 2 | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | July 2010 | June 2014 |
| NCT01272817 | Completed | N/A | Nonmyeloablative Allogeneic Transplant | October 2001 | October 2015 |
| NCT01338987 | Completed | Phase 2 | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation | April 19, 2011 | November 19, 2020 |
| NCT01350245 | Completed | Phase 2 | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | July 2010 | May 2014 |
| NCT01363297 | Completed | Phase 2 | Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia | August 2011 | January 2016 |
| NCT01474681 | Completed | Phase 1/Phase 2 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | January 9, 2012 | October 3, 2016 |
| NCT01491958 | Completed | Phase 2 | Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation | December 10, 2011 | June 27, 2016 |
| NCT01572662 | Completed | Phase 2 | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | April 11, 2012 | August 11, 2022 |
| NCT01586455 | Completed | Phase 1 | Human Placental-Derived Stem Cell Transplantation | April 2013 | September 2022 |
| NCT01597778 | Completed | Phase 3 | Double Cord Versus Haploidentical (BMT CTN 1101) | June 2012 | September 11, 2020 |
| NCT01600781 | Completed | N/A | Effect of Oral Supplementation With a Fibre Enriched Paediatric Sip Feed For Children With Acute Lymphocytic Leukemia | December 2011 | September 2014 |
| NCT01634217 | Completed | Phase 1 | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | November 8, 2013 | December 1, 2018 |
| NCT01702155 | Completed | Phase 1/Phase 2 | Phase I/II Study of DFP-10917 in Patients With Acute Leukemia | October 10, 2012 | October 11, 2017 |
| NCT01930162 | Completed | Phase 2 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant | October 7, 2014 | August 29, 2016 |
| NCT01965171 | Completed | Transfusional Iron Overload Among Leukemia Survivors | October 18, 2013 | May 2017 | |
| NCT02007863 | Completed | N/A | Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia | August 2008 | June 2014 |
| NCT02129582 | Completed | Phase 1 | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies | November 5, 2014 | March 5, 2020 |
| NCT02141828 | Completed | Phase 1 | A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene | May 2014 | June 2016 |
| NCT02374333 | Completed | Phase 1 | Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy | March 25, 2014 | September 2, 2021 |
| NCT02410252 | Completed | N/A | Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies | May 2015 | August 2017 |
| NCT02581007 | Completed | Phase 2 | Reduced Intensity Conditioning Transplant Using Haploidentical Donors | October 26, 2015 | December 28, 2020 |
| NCT02593123 | Completed | Phase 2 | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | November 4, 2015 | March 18, 2022 |
| NCT02661035 | Completed | Phase 2 | Allo HSCT Using RIC for Hematological Diseases | March 9, 2017 | May 29, 2023 |
| NCT02670252 | Completed | Phase 3 | BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT | January 2016 | February 2022 |
| NCT02914977 | Completed | Phase 1 | Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia | November 2016 | July 15, 2021 |
| NCT03056339 | Completed | Phase 1/Phase 2 | Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | June 21, 2017 | March 6, 2023 |
| NCT03076437 | Completed | Phase 1/Phase 2 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | January 15, 2016 | December 31, 2019 |
| NCT03263637 | Completed | Phase 1 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | October 24, 2017 | September 30, 2021 |
| NCT03555955 | Completed | Phase 1 | A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 | November 20, 2018 | May 26, 2021 |
| NCT04629430 | Completed | N/A | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT | February 19, 2021 | October 28, 2022 |
| NCT05021159 | Completed | Assessing the Ontogeny of P-glycoprotein Expression in Blood of Pediatric Leukemic Patients | March 1, 2020 | August 1, 2021 | |
| NCT05456698 | Not yet recruiting | Phase 2 | Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy | August 1, 2022 | June 30, 2025 |
| NCT03104491 | Recruiting | Phase 1/Phase 2 | Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | July 31, 2017 | May 2026 |
| NCT05775406 | Recruiting | Phase 1 | Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors | May 15, 2023 | November 2025 |
| NCT04771572 | Recruiting | Phase 1 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | August 23, 2021 | October 1, 2025 |
| NCT01890486 | Recruiting | The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | May 21, 2001 | December 2025 | |
| NCT01853631 | Recruiting | Phase 1 | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | February 2014 | February 2036 |
| NCT03934372 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | January 29, 2020 | January 4, 2025 |
| NCT05727683 | Recruiting | Phase 1 | CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia | April 28, 2022 | July 31, 2025 |
| NCT05044039 | Recruiting | Phase 1 | Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy | February 28, 2022 | May 31, 2030 |
| NCT03633955 | Recruiting | Phase 1 | Pilot Imaging Study of Leukemia | January 19, 2023 | April 2027 |
| NCT05811910 | Recruiting | Genetic Polymorphisms in Drug Induced Neuropathy in Children With ALL | March 30, 2021 | December 31, 2023 | |
| NCT03448393 | Recruiting | Phase 1 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | March 26, 2018 | December 31, 2040 |
| NCT05805605 | Recruiting | Phase 2 | Allo HSCT Using RIC and PTCy for Hematological Diseases | May 1, 2023 | October 22, 2028 |
| NCT06131801 | Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | November 15, 2023 | December 1, 2027 | |
| NCT05442515 | Recruiting | Phase 1/Phase 2 | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | December 28, 2022 | July 1, 2029 |
| NCT01049113 | Terminated | Phase 1 | Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia | November 2009 | December 2015 |
| NCT02750254 | Terminated | Phase 1 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | June 27, 2016 | October 14, 2020 |
| NCT00963495 | Terminated | Phase 1 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | August 2009 | September 2013 |
| NCT00594308 | Terminated | N/A | In-Vivo Activated T-Cell Depletion to Prevent GVHD | October 2007 | |
| NCT00852709 | Terminated | Phase 1 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias | September 1, 2007 | November 20, 2009 |
| NCT01500161 | Terminated | Phase 2 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | November 2011 | November 2013 |
| NCT01551043 | Terminated | Phase 1 | Allo CART-19 Protocol | September 2010 | June 2016 |
| NCT00430443 | Terminated | Phase 1 | Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML | February 2007 | January 2009 |
| NCT03696537 | Terminated | Phase 1 | IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT | August 29, 2018 | April 13, 2021 |
| NCT01745913 | Terminated | Phase 2 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies | October 26, 2012 | April 29, 2015 |
| NCT02043587 | Terminated | Phase 2 | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | January 2014 | April 14, 2022 |
| NCT03191773 | Unknown status | Phase 1/Phase 2 | A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies | June 30, 2017 | December 31, 2020 |
| NCT02851589 | Unknown status | Phase 1/Phase 2 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | July 2016 | November 2019 |
| NCT00271063 | Unknown status | Phase 1/Phase 2 | Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia | October 2005 | April 2008 |
| NCT02819583 | Unknown status | Phase 1/Phase 2 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | October 2016 | September 2019 |
| NCT04004637 | Unknown status | Phase 1 | CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia | August 25, 2019 | June 1, 2021 |
| NCT00155844 | Unknown status | Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier" | February 2003 | July 2004 | |
| NCT01037556 | Unknown status | Phase 1/Phase 2 | PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia | January 2010 | December 2012 |
| NCT03088709 | Unknown status | Phase 2 | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | January 18, 2017 | January 31, 2022 |
| NCT01310946 | Unknown status | Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology | June 2003 | ||
| NCT02892695 | Unknown status | Phase 1/Phase 2 | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | September 2016 | September 2019 |
| NCT00149136 | Unknown status | Phase 2 | Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy. | August 2002 | |
| NCT02456350 | Unknown status | Phase 1 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | April 2015 | December 2019 |
| NCT04796675 | Unknown status | Phase 1 | Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies | April 10, 2021 | March 10, 2024 |
| NCT00304720 | Unknown status | Phase 2 | Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor | March 2004 | |
| NCT03840317 | Unknown status | Phase 1 | Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia | January 2, 2019 | January 31, 2022 |
| NCT05410041 | Unknown status | Phase 1 | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies | May 25, 2022 | May 2024 |
| NCT02765997 | Withdrawn | Phase 2 | StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies | April 2017 | June 2022 |
| NCT01163201 | Withdrawn | Phase 1/Phase 2 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | January 2014 | January 2015 |
| NCT03066466 | Withdrawn | Phase 3 | Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT | December 10, 2019 | February 28, 2021 |
| NCT01162031 | Withdrawn | Phase 2 | Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia | June 2010 | July 2011 |
| NCT05170828 | Withdrawn | Phase 1 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | September 2022 | November 2024 |
| NCT05201183 | Withdrawn | Phase 1/Phase 2 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies | October 2023 | April 2029 |